Mochida Pharmaceutical has been granted a patent for methods and compositions to determine sepsis in individuals. The patent involves the use of specific antibodies or fragments that bind to presepsin, a biomarker for sepsis. The invention also includes kits containing these antibodies for diagnostic purposes. GlobalData’s report on Mochida Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mochida Pharmaceutical, cancer treatment biomarkers was a key innovation area identified from patents. Mochida Pharmaceutical's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is granted for an anti-presepsin antibody
A recently granted patent (Publication Number: US11685788B2) discloses an invention related to anti-presepsin monoclonal antibodies and antigen-binding antibody fragments. The patent claims an antibody or antibody fragment that specifically binds to an epitope of presepsin, which is represented by SEQ ID NO: 1.
Presepsin is a biomarker that has been associated with sepsis, a life-threatening condition caused by a severe infection. The invention described in the patent aims to provide a specific antibody or antibody fragment that can target presepsin and potentially be used for diagnostic or therapeutic purposes.
Claim 1 of the patent states that the antibody or antibody fragment specifically binds to an epitope of presepsin consisting of SEQ ID NO: 1. This means that the antibody or fragment has been designed to recognize and bind to a specific region of presepsin, allowing for targeted detection or treatment of sepsis.
Claim 2 further specifies that the antibody fragment can be selected from various types, including Fab, Fab', F(ab')2, single-stranded antibody (scFv), dimerized V region (diabody), disulfide-stabilized V region (dsFv), and sc(Fv)2. These different types of antibody fragments offer flexibility in terms of their structure and potential applications.
Overall, this granted patent highlights the development of an anti-presepsin monoclonal antibody or antibody fragment that specifically binds to a specific region of presepsin. This invention has the potential to contribute to the diagnosis and treatment of sepsis, a critical medical condition. Further research and development based on this patent could lead to the creation of novel diagnostic tools or therapeutic interventions for sepsis patients.
To know more about GlobalData’s detailed insights on Mochida Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
